Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects

NCT00542529 is registered in ClinicalTrials.gov with HiberCell, Inc. as lead sponsor.

NCT NCT00542529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00542529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects
Lead sponsor
HiberCell, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2006
Completion date
December 31, 2006
Enrollment
66 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy